Bruker’s Revenue, Profits up Sharply in Q3 on Optics Acquisition
 
Bruker Biosciences’ third-quarter revenue increased 22 percent as income jumped by a third, the company said last week.
 
Receipts for the three months ended Sept. 30 rose to $104.8 million from $85.9 million year over year. Product revenues were up 22 percent to $50.1 million and receipts from the company’s services business tallied $8 million, a third more than the same period last year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.